造血干细胞移植可逆转DADA2的血液学、免疫学及血管表型
本文报告来自6个国家的14例因骨髓功能障碍或免疫缺陷接受造血干细胞移植的DADA2患者。移植后中位随访18个月,全部存活且无新发血管事件,血液学与免疫学表型均缓解,7例受检者血浆ADA2酶活性于移植后恢复正常。
要点
- 14例DADA2患者因骨髓功能障碍或免疫缺陷接受HSCT,中位移植年龄7.5岁。
- 中位随访18个月,全部存活,无新发血管事件,血液学与免疫学表型缓解。
- 移植后7例受检者血浆ADA2酶活性均恢复正常,最早见于+14天(髓系植入)。
核心结论
- 在14例患者中,HSCT是DADA2有效且确切的治疗方法。
研究设计与样本
- 本文报告来自6个国家的14例因骨髓功能障碍或免疫缺陷接受HSCT的DADA2患者队列。
- 移植前6/14例存在血管炎;移植时中位年龄7.5岁。
- 预处理方案为清髓性(9例)和减低强度(5例);供者包括HLA相合同胞(1例)、HLA相合无关(9例)、HLA不合无关(3例)和HLA单倍体相合同胞(1例)。
主要发现
- 中位随访18个月(范围5个月至13年),全部患者存活且无新发血管事件,血液学与免疫学表型缓解。
- 移植后受检者血浆ADA2酶活性均恢复正常(7/7),最早见于+14天(髓系植入)。
- 移植后4例报告血液学自身免疫(血细胞减少);急性移植物抗宿主病1级2例、2级3例、3-4级1例;中度慢性移植物抗宿主病1例。
关键数值与推荐
- HSCT指征为骨髓功能障碍或免疫缺陷。
- 肿瘤坏死因子-α阻断是自身炎症和血管表现的首选治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deficiency of adenosine deaminase 2 (DADA2) is caused by biallelic deleterious mutations in CECR1 DADA2 results in variable autoinflammation and vasculopathy (recurrent fevers, livedo reticularis, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages), immunodeficiency and bone marrow failure. Tumor necrosis factor-α blockade is the treatment of choice for the autoinflammation and vascular manifestations. Hematopoietic stem cell transplantation (HSCT) represents a potential definitive treatment. We present a cohort of 14 patients from 6 countries who received HSCT for DADA2. Indication for HSCT was bone marrow dysfunction or immunodeficiency. Six of 14 patients had vasculitis pre-HSCT. The median age at HSCT was 7.5 years. Conditioning regimens were myeloablative (9) and reduced intensity (5). Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical sibling (n = 1). All patients are alive and well with no new vascular events and resolution of hematological and immunological phenotype at a median follow-up of 18 months (range, 5 months to 13 years). Plasma ADA2 enzyme activity normalized in those tested post-HSCT (7/7), as early as day +14 (myeloid engraftment). Post-HSCT hematological autoimmunity (cytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in 3, and grade 3-4 in 1, and moderate chronic graft-versus-host disease in 1 patient. In conclusion, in 14 patients, HSCT was an effective and definitive treatment of DADA2.
引用
- Hashem H, Kumar AR, Müller I, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017. PMID: 28974505. doi:10.1182/blood-2017-07-798660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。